IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a leading precision medicine oncology company, today announced that the first patient has been enrolled in its Phase 1 clinical trial evaluating IDE892, an ...
South San Francisco, California Tuesday, March 10, 2026, 17:00 Hrs [IST] ...
一名23岁男性患者因癫痫发作就诊,意外揭示了一个跨越三代家族成员、涉及多种致命性癌症的罕见遗传性疾病。在首次手术切除低级别星形细胞瘤八年之后,该患者于大脑两个独立部位“同时”出现了组织学类型与遗传背景完全不同的新发肿瘤——其中一个为多形性黄色星形细胞瘤,另一个为弥漫性星形细胞瘤,同时影像学检查还发现一处疑似椎旁神经鞘瘤的病变。面对如此复杂且罕见的颅内“多原发”肿瘤,结合其家族中黑色素瘤、脑胶质瘤及 ...
南旧金山 - Ideaya Biosciences(NASDAQ:IDYA)周一在新闻稿中宣布,其针对MTAP缺失实体瘤的研究性MTA协同PRMT5抑制剂IDE892的1期临床试验已完成首位患者入组。这家市值29.1亿美元的生物技术公司表现亮眼,过去一年股价上涨近80%。 该试验将评估IDE892作为单药疗法在MTAP缺失实体瘤患者中的安全性、耐受性、药代动力学和药效学,包括非小细胞肺癌和胰腺癌患 ...
Since the discovery of RAS gene mutations in DNA from human tumours around 40 years ago, KRAS has emerged as the most frequently mutated oncogene in human cancer, particularly in pancreatic, ...
Phothera, the leading manufacturer of FDA-cleared light therapy devices for chronic skin conditions including vitiligo, psoriasis, atopic dermatitis, and cutaneous T-cell lymphoma (CTCL), today ...
INC国际儿童脑瘤领域权威专家、世界小儿神经系统专业杂志《Child's Nervous System》现任主编Concezio Di Rocco教授发表研究《Subgroup specific structural variation across 1,000 medulloblastoma genomes》(对1000余例髓母细胞瘤基因组进行亚组特异性结构变异分析),以下为该项研究的详细内容解 ...
Chicago Faucets, a Geberit Group company and leader in commercial plumbing fittings, is making its first appearance at the 2026 PDC Summit Booth #920 - March 9-11, 2026 in Houston, Texas.  The company ...
用特异性捕获抗体包被酶标板,结合样本中的IGSF9;洗涤后加入生物素化检测抗体,形成“固相抗体-抗原-检测抗体”复合物;再加入辣根过氧化物酶(HRP)标记的亲和素,催化TMB底物显色,颜色深浅与IGSF9浓度呈正比,450 nm测定OD值并计算浓度。 建议通过预实验 ...
Enhancer hijacking emerges as a major “missing driver” mechanism in LBCL/PCN, enabling detection of non-chimeric oncogene activation such as IGL::BCL2, IGH::CCND2, and MAFA/MAFB rearrangements.
2026年3月2日,北京大学肿瘤医院柯杨/何忠虎课题组在BMC Medicine发表题为“Is Random Biopsy Necessary for Normal Esophageal Mucosa During Chromoendoscopy? Evidence from a Population-based Cohort Study”的研究报告。该研究依托该课题组在食管癌高发区开展的“评价内 ...